Risk of atypical mycobacterial infections in psoriasis patients during IL-17 inhibitor therapy

J Dermatolog Treat. 2021 Aug;32(5):495-496. doi: 10.1080/09546634.2019.1687812. Epub 2019 Nov 12.

Authors

Vipawee S Chat¹, Donovan G Kearns², Shelley K Uppal³, Jashin J Wu⁴

Affiliations

¹ Medical College of Georgia at Augusta University, Augusta, GA, USA.
² Loma Linda School of Medicine, Loma Linda, CA, USA.
³ Albany Medical College, Albany, NY, USA.
⁴ Dermatology Research, Education Foundation, Irvine, CA, USA.

PMID: 31689137
DOI: 10.1080/09546634.2019.1687812

No abstract available

Publication types

Letter

MeSH terms

Humans
Interleukin-17 / antagonists & inhibitors*
Mycobacterium Infections, Nontuberculous* / etiology
Psoriasis* / drug therapy
Risk Factors

Substances

Interleukin-17